Emergence of Integrase Resistance Mutations During Initial Therapy Containing Dolutegravir.
Ontology highlight
ABSTRACT: Dolutegravir (DTG) is a preferred drug for initial treatment of human immunodeficiency virus type 1 infection. We present next-generation sequencing analysis of integrase genotypes during a period of virologic failure in a treatment-naive man who initiated tenofovir disoproxil fumarate/emtricitabine plus DTG.
SUBMITTER: Fulcher JA
PROVIDER: S-EPMC6093998 | biostudies-literature |
REPOSITORIES: biostudies-literature
ACCESS DATA